Like all drug firms with a Facebook presence, Pfizer lost some control in August when Facebook opened up pharma company pages to public commenting. But that was relatively mild compared to the loss of power it suffered in July at the hands of a group of hackers calling themselves the Script Kiddies.
Leaders never follow, goes the adage. But on your way to the top, it couldn’t hurt to emulate these biopharmaceutical executives, whose career steps got them to the top of the industry. Marc Iskowitz reports
Eliquis has demonstrated, in convincing fashion, that it’s superior in efficacy and bleeding profile to standard warfarin therapy, and neither Pradaxa nor Xarelto can match it in overall mortality or safety.
Experts are looking forward to an international cardiology meeting this weekend to help answer a key question: Will Eliquis become the leading substitute for warfarin?
Corporate logos may still appear in CME commercial support disclosures, ACCME said, after a majority of respondents expressed disapproval of its proposal to ban them.
Doctors chip in more for CME, drugmakers less: report
The drug industry’s backing of certified CME fell for a third straight year, as registration fees and other income surged, just-released data from ACCME show.
Recent Pfizer CME grants take non-clinical approach
In a sign of industry’s ongoing desire to broaden its CME funding outlook, a couple of recently supported educational programs by Pfizer aim to foster practice-based improvement as they seek to advance the science of CME.
Feds subpoena Merck on marketing of hepatitis, cancer drugs
A rival’s whistleblower lawsuit ostensibly turned on allegations of bad billing but was really a bid to stifle competition, argues Millennium Labs in a motion to dismiss the suit. Millennium president Howard Appel explains why the suit he’s contesting is not about reimbursement.